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Abstract
The objective of this study was to assess the association of sex and the apolipoprotein E (APOE) ε4 allele with
brain tau deposition and atrophy in older adults with Alzheimer’s disease (AD) using quantitative 18F-AV-1451
positron emission tomography (PET) and magnetic resonance imaging (MRI).
Methods: Preprocessed 18F-AV-1451 tau PET, raw T1-weighted structural MR images, demographic
information, cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau (p-tau) measurements from 57
elderly individuals with AD were downloaded from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database. An iteratively reblurred Van Cittert partial volume correction (PVC) method was applied to all
preprocessed PET images. MRI images were used for PET spatial normalization and gray matter volume
calculation. 18F-AV-1451 PET standardized uptake value ratio (SUVR) was calculated relative to the cerebellum
gray matter. The effect of sex and APOE ε4 status on SUVR and gray matter volume were assessed at both
region of interest (ROI) and voxelwise levels.
Results: Female APOE ε4 carriers (FACs) had significant higher 18F-AV-1451 SUVRs in the lateral temporal,
parietal, posterior cingulate, medial temporal, inferior temporal, entorhinal cortex, amygdala and
parahippocampal gyrus regions, and exhibited smaller gray matter volumes in the posterior cingulate, medial
temporal, inferior temporal and amygdala regions, as compared to the non-FACs (NFACs) comprised of female
APOE ε4 non-carriers, male APOE ε4 carriers and male APOE ε4 non-carriers. Voxelwise analysis revealed
forebrain and limbic clusters with greater 18F-AV-1451 SUVRs and lower gray matter volume between FACs
compared to the NFACs. Negative correlations between ROI 18F-AV-1451 SUVRs and gray matter volumes
were significant after adjusting for age and years of education.
Conclusions: Among elderly individuals with AD, sex modified the effects of the APOE ε4 allele on
region-specific tau deposition and gray matter volume. FACs had elevated brain region-specific tau PET SUVR
and decreased gray matter volume in comparison to NFACs. The study provides a basis for the use of precision
medicine in the diagnosis of AD and evaluation of therapeutics using 18F-AV-1451 PET and structural MRI.
Key words: Alzheimer’s disease, Tau PET, Sex, APOE, Neurodegeneration

Introduction
The apolipoprotein E (APOE) ε4 gene has
emerged as a major genetic risk factor for Alzheimer’s
disease (AD) [1-3]. APOE ε4 is associated with ADrelated biological markers including cerebrospinal
fluid (CSF) total tau (t-tau), phosphorylated tau

(p-tau), brain tau deposition, and gray matter atrophy
[4-9].
In addition to APOE ε4, sex also plays an
important role in AD risk, with females having a
higher lifetime risk of developing AD than males [10,
11]. Sex differences in brain tau pathology and neurohttp://www.thno.org
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degeneration have been identified in healthy older
adults and patients with AD [12-14]. The Lancet
Neurology Commission has recently asserted that
greater attention to sex differences in AD is essential
to advancing both disease prevention and treatment
strategies in AD [15].
Numerous CSF and epidemiological evidence
support modulatory effects of APOE ε4 on sex-specific
disease risk and neuropathology in AD. For example,
female APOE ε4 carriers (FACs) have a greater risk of
developing AD [16, 17] and far more pronounced
disease progression [18]. Studies of CSF t-tau and
p-tau have suggested that FACs accumulate more tau
pathology than males in clinically normal older adults
[19], patients with mild cognitive impairment (MCI)
[18], and even mixed diagnostic cohorts (clinically
normal older adults, MCI and AD) [13]. In addition,
emerging evidence suggests that the cortical tau
measured by quantitative positron emission
tomography (PET) is temporally and prospectively
related to the degree of neurodegeneration and
current cognitive status [20-23]. Two recent studies
have investigated how sex modulates the effect of
APOE ε4 on brain tau deposition using quantitative
18F-AV-1451 PET. One study focused on clinically
normal individuals in a 2-cohort study, and showed a
significant sex by APOE ε4 interaction effect on
regional tau retention [12]. Our previous work
reported a significant APOE ε4 by sex interaction
effect on regional brain tau deposition in individuals
with MCI [24]. These two studies suggest that FACs
exhibit brain regions with increased tau deposition
among cognitively normal older adults and
individuals with MCI.
Cross-sectional structural magnetic resonance
imaging (MRI) studies have shown a similar APOE ε4
interaction effect on gray matter atrophy. In MCI, the
effect of APOE ε4 on hippocampal volume reduction
was stronger in females versus males [25]. Similarly
among AD patients, FACs had significantly smaller
hippocampal volume compared to female APOE ε4
non-carriers, which, however, was not observed in
males [9].
Understanding these APOE ε4 by sex interaction
effects may help us identify and apply customized
prevention strategies for different populations against
AD. The evidence of how sex in association with
APOE ε4 affects tau PET and gray matter volume, and
whether tau pathology is associated with neurodegeneration in patients with AD remain poorly
understood. The objective of the present study was to
assess whether sex modulates the effects of the APOE
ε4 allele on brain tau deposition and atrophy in older
adults with AD.
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Methods
Participants
We included 57 participants from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
who had (i) a clinical diagnosis of AD, (ii) undergone
18F-AV-1451 tau PET, (iii) high resolution 3D
T1-weighted structural MRI, and (iv) APOE ε4
genotyping information. Consent was obtained from
all participants prior to the start of the study. For each
subject, the most recent tau PET and T1-weighted MRI
scan were included. A full list of study inclusion and
exclusion criteria can be found at https://adni.loni.
usc.edu/wp-content/uploads/2008/07/adni2-proce
dures-manual.pdf.

PET and MRI data acquisition and processing
Preprocessed 18F-AV-1451 PET images and raw
T1-weighted images were downloaded from the
ADNI database (http://adni.loni.usc.edu/). The
18F-AV-1451 PET acquisition parameters can be found
at http://adni.loni.usc.edu/methods/pet-analysismethod/pet-analysis/. The PET images had been
previously aligned, averaged, reoriented and interpolated into a standard image space with uniform
voxel size (image volume 160 × 160 × 96, 1.5 × 1.5 × 1.5
mm3 in x, y, z), and then were smoothed to a uniform
resolution of 8 mm in full width at half maximum
(FWHM) by the ADNI consortium.
As described in our previous studies [24, 26], we
further processed the downloaded PET images for
partial volume correction (PVC) and spatial
normalization using Statistical Parametric Mapping
(SPM12, Wellcome Department of Imaging
Neuroscience, Institute of Neurology, London, UK)
with CAT12 toolbox (CAT12: http://www.neuro.unijena.de/cat/) and MATLAB R2019b (The MathWorks
Inc). PVC was applied to the processed PET images to
correct for or minimize potential underestimation in
PET quantification. In brief, an iterative reblurred Van
Cittert method [27] was used for PVC on the PET
images. The algorithm was implemented using a 3-D
Gaussian kernel with 8 mm FWHM, step length α
=1.5, and an iteration stop criterion of relative percent
change of PVC images < 1%. All PET images with
PVC were then coregistered to the corresponding
structural MRI images. The MRI images were
normalized to standard Montreal Neurologic Institute
(MNI) space using SPM12 with a MRI template
(image volume: 121×145×121, voxel size: 1.5×1.5×1.5
mm3 in x, y, z). The transformation parameters
determined by MRI spatial normalization were then
applied to the coregistered PET images for PET spatial
normalization. Regions of interest (ROIs) including
cerebellum gray matter as a reference tissue were
http://www.thno.org
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manually drawn on the MRI template using PMOD
(version 4.002; PMOD Technologies Ltd., Zürich,
Switzerland) in standard MNI space. SUVR images
were calculated relative to the cerebellum gray matter.
SUVR images without PVC were also generated for
reference.
Braak Stage related 12 ROIs, including the
entorhinal cortex, parahippocampal, amygdala,
inferior temporal, medial temporal, lateral temporal,
posterior cingulate, posterior precuneus, parietal,
occipital, orbital frontal, and prefrontal, were also
defined in the MNI space [22, 24, 26]. The SUVR of
each ROI was obtained by calculating the mean of the
values within each ROI on the PVC and without PVC
PET images in the MNI space. The choice to compute
ROI SUVRs in standard space was made to minimize
variance related to the variability of ROI volume and
shape in native space [24, 26, 28, 29].
Gray matter volume was calculated using the
CAT12 toolbox extension of SPM12. CAT12
preprocessing was conducted following the standard
default procedure suggested in the manual. First,
structural T1-weighted MRI images were segmented
into gray matter, white matter and CSF. Then, gray
matter segmentations were warped to MNI space
with modulated spatial normalization. Finally, the 12
cortical ROIs gray matter volumes were calculated
from the modulated gray matter images.

APOE genotyping, CSF t-tau and p-tau
assessment
A 10 ml sample of peripheral blood was
collected from each subject for direct APOE
genotyping. Restriction enzyme isoform genotyping
was performed on the extracted DNA to test for the
presence of the APOE ε4 genotype, as described
previously [30]. APOE ε4 carriers were defined as
participants who had one or more ε4 allele (ε4/ ε4, ε4/
ε3 and ε4/ ε2). Those without any ε4 allele were
defined as APOE ε4 non-carriers. CSF samples were
acquired through lumbar puncture as described in
ADNI:
http://adni.loni.usc.edu/methods/
documents/. The Roche study protocol developed by
the UPenn/ADNI Biomarker Laboratory was used for
Aβ42, t-tau, and p-tau CSF quantification, as
described in previously [31, 32].

Statistical analysis
Recent studies have found no significant
differences among non-FACs (NFACs, including
female APOE ε4 non-carriers, male APOE ε4 carriers
and male APOE ε4 non-carriers) in 18F-AV-1451 ROI
SUVRs in cognitively normal adults [12] and
individuals with MCI [24]. In the current tau PET
study, we first tested the hypothesis that previous
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results from cognitively normal and MCI cohorts hold
true in our AD cohort. Statistical analysis using
generalized linear models (GLMs) proc with
LS-means/pdiff, implemented in Statistical Analysis
System (SAS version 9.4, SAS Institute, Inc.),
confirmed that 18F-AV-1451 SUVR did not
significantly differ among NFACs in any of the 12
study ROIs. Specifically, no regions were significantly
different in an overall test of significance between
NFAC groups with P values ranging from 0.19 for the
medial temporal to 0.99 for the occipital. Likewise, in
pairwise intergroup comparisons (i.e. female APOE ε4
non-carriers vs. male APOE ε4 carriers, female APOE
ε4 non-carriers vs. male APOE ε4 non-carriers, and
male APOE ε4 carriers vs. male APOE ε4
non-carriers), no regions were significantly different
with P values ranging from 0.09 for the inferior
temporal female APOE ε4 non-carriers vs. male APOE
ε4 non-carriers in comparison to 0.99 for the posterior
precuneus female APOE ε4 non-carriers vs. male
APOE ε4 carriers comparison. Based on this finding,
in order to increase statistical power, all subsequent
analyses compared FACs to the NFACs. SAS9.4 and
SPM12 were used for all statistical analyses. GLMs
adjusted for age and years of education were used to
assess group differences in SUVR and gray matter
volume for both ROI and voxelwise analyses. For ROI
analyses, P < 0.05 was considered significant. For
voxelwise analyses, an uncorrected P < 0.001 and
cluster size > 100 voxels were defined as significant.
Additional
statistical
results
with
multiple
comparison corrections are discussed in the
Discussion section. To investigate whether regional
tau retention was associated with neurodegeneration,
the correlation between ROIs 18F-AV-1451 SUVRs and
gray matter volume was analyzed using partial
correlation analysis.

Results
Demographics
A total of 57 AD subjects (mean age: 78.98 ± 9.22
years, 25 females (44%), 34 APOE ε4 carriers (60%))
with 18F-AV-1451 PET and structural MRI scans were
included in the study. Demographic characteristics,
cognitive function and CSF Aβ42, t-tau and p-tau
levels of FACs and NFACs are listed in Table 1. There
were no significant differences in age and years of
education between males and females for either the
APOE ε4 carrier group or the non-carrier group (P >
0.05). Performance on the Mini-Mental State
Examination (MMSE), global Clinical Dementia
Rating (CDR) and CDR-sum of boxes (CDR-SOB)
score (P > 0.05) were not significantly different among
the four subgroups, after adjusting for age and years
http://www.thno.org
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of education. Chi-squared analysis revealed no
significant difference in the proportion of individuals
with APOE ε4 ε4/ ε4 ε3/ ε4 ε2 genotypes (P = 0.95)
between males and females.
Table 1. Study cohort characteristics
Parameter
Age (years)
Education (years)
MMSE
Global CDR
CDR-SOB
APOE
ε4ε4/ε4ε3/ε4ε2
CSF Aβ42 (pg/mL)
CSF t-tau (pg/mL)
CSF p-tau (pg/mL)

Female APOE
ε4+ (n = 15)
76.58±7.98
14.73±1.94
21.20±4.59
1.13±0.48
1.38±1.90
5/8/2

Female APOE
ε4- (n = 10)
79.26±11.60
13.50±2.01
20.10±5.86
1.20±0.59
3.56±4.27
-

Male APOE
ε4+ (n = 19)
79.32±8.63
17.11±2.62
22.79±4.40
0.87±0.50
1.46±2.79
6/11/2

Male APOE
ε4- (n = 13)
81.06±9.86
16.00±2.71
22.15±5.16
0.88±0.42
1.00±1.84
-

589.56±180.47 795.35±262.64 625.24±195.16 722.17±343.62
433.03±202.33 343.43±191.15 341.76±109.82 333.44±180.90
43.31±25.37
31.60±21.84
34.19±11.86
33.34±21.58

Notes. CDR: Clinical Dementia Rating; CDR-SOB: Clinical Dementia Rating Scale
sum of boxes; CSF: cerebrospinal fluid; MMSE: Mini-Mental State Examination.

Sex modifies the APOE ε4 effect on brain tau
deposition measured by 18F-AV-1451 PET
SUVR
Mean 18F-AV-1451 SUVR images in Figure 1
visually demonstrate that FACs have higher SUVR in
both PVC and without PVC images in comparison the
NFACs. Compared to the without PVC images
(Figure 1B), the mean 18F-AV-1451 SUVR images with
PVC in Figure 1A exhibit a higher SUVR contrast
between APOE ε4 carriers and non-carriers, consistent
with our previous study [22]. Based on this finding,
PVC images were retained for subsequent analyses.
After adjusting for age and years of education,

ROI analysis revealed significantly higher ROI SUVRs
between FACs compared to the NFACs with AD in
the lateral temporal, parietal, posterior cingulate,
medial temporal, inferior temporal, entorhinal cortex,
amygdala and parahippocampal gyrus (P < 0.05;
Figure 2). Voxelwise analysis revealed higher SUVR
between FACs compared to the NFACs with AD in
clusters corresponding to the bilateral middle
temporal, middle temporal pole, inferior temporal,
entorhinal cortex, parahippocampal gyrus, amygdala,
left superior temporal, parietal, middle occipital,
precentral, middle frontal, superior frontal and
middle orbitofrontal lobe (P < 0.001, Figure 3, Table 2)
after adjusting for age and years of education.

Sex modifies the APOE ε4 effect on gray
matter volume measured by structural MRI
ROI-based analysis revealed significantly lower
gray matter volume among FACs compared to the
NFACs in the posterior cingulate, medial temporal,
inferior temporal and amygdala after adjusting for
age and years of education (P < 0.05; Figure 4). In
voxelwise analysis, FACs had decreased gray matter
volume in clusters located in the left inferior temporal,
inferior occipital, middle temporal, middle occipital,
amygdala, posterior cingulate; right superior
temporal pole, superior occipital, precuneus, bilateral
superior-medial frontal, supplementary motor area
and superior frontal lobe compared to the NFACs
after adjusting for age and years of education (P <
0.001, Figure 5, Table 3).

Figure 1. Mean SUVR images of 18F-AV-1451 PET with and without partial volume correction in individuals with AD. Partial volume corrected SUVR images (A)
show increased contrast and spatial resolution compared with the images without PVC (B). Both with and without PVC images visually demonstrate that FACs have higher
18F-AV-1451 SUVR. FACs: female APOE ε4 carriers, PVC: partial volume correction.

http://www.thno.org
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Figure 2. The FACs have higher ROI 18F-AV-1451 PET SUVRs relative to NFACs with AD. Mean (±standard deviation) of ROI 18F-AV-1451 PET SUVR for FACs
(red) and NFACs with AD (blue) are depicted. P value was determined by a generalized linear model with age, years of education included as covariates. FACs: female APOE ε4
carriers, NFACs: non-FACs, SUVR: standardized uptake value ratio.

Figure 3. 18F-AV-1451 SUVR voxelwise difference between FACs and
NFACs with AD. T values are expressed in blue-red colors from 0 to 5 (P < 0.001,
uncorrected, adjusted for age and years of education). FACs: female APOE ε4
carriers, NFACs: non-FACs.

Association between tau SUVR and gray
matter volume
We then sought to identify associations between
tau deposition and gray matter volume. 18F-AV-1451
SUVR was associated with gray matter volume of the
temporal, parietal, posterior precuneus, occipital,
entorhinal cortex, amygdala and parahippocampal
regions (P < 0.05, Figure 6).

Discussion
By extending previous work on APOE ε4-sex
interaction effects on brain tau deposition in
cognitively normal and MCI cohorts [12, 24], our

study revealed that sex also modifies the effect of
APOE ε4 on brain tau deposition and atrophy in
individuals with AD using data from the ADNI
consortium. Recent work on clinically normal
individuals from the Harvard Aging Brain Study
found no sex-APOE ε4 interaction effect on regional
tau deposition. However, within the ADNI cohort, a
sex by APOE ε4 interaction effect on brain tau
deposition was previously found in the early Braak
stages (Ⅰ-Ⅲ) regions including the entorhinal cortex,
inferior
temporal,
amygdala,
fusiform
and
parahippocampal gyrus [12, 33]. For individuals with
MCI, sex-stratified analysis showed that FACs had
higher tau SUVR in the entorhinal cortex, amygdala,
fusiform,
parahippocampal
gyrus,
posterior
cingulate, occipital, temporal, parietal and posterior
precuneus (Braak stages Ⅰ-Ⅴ) compared to NFACs
[24]. In this study, we focused on older adults with
AD, and found that FACs had more tau deposition in
the temporal, parietal, post cingulate, entorhinal
cortex, amygdala, parahippocampal gyrus (Braak
stages Ⅰ-Ⅴ) regions compared to the NFACs. Overall,
our results add to a growing body of work
demonstrating an APOE ε4 and sex interaction effect
in AD whereby FACs exhibit greater brain
region-specific tau deposition compared to NFACs
across sub-clinical and clinical stages of AD.
Recent metabolic and transcriptomic data add
potential mechanistic explanations to the findings of
this study [34-37]. For example, prior work has found
that specific metabolic effects were limited to FACs. A
recent study found that, among FACs, higher
acylcarnitine C10 was associated with higher CSF
p-tau, and higher proline levels were associated with
reduced brain glucose uptake. These effects were not
http://www.thno.org
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observed in the NFACs, suggesting that FACs
experience greater impairment of mitochondrial
energy production compared to NFACs with AD [36].
This provides an additional line of support for the
findings drawn in this work. Moreover, in-vitro and
transcriptomic data has suggested that sex modulates
neuroinflammation, another risk factor for AD, with
inflammatory dysregulation being stronger in females
with AD [37, 38]. APOE ε4 also triggers neuroinflammatory cascades that cause neurovascular
dysfunction resulting in leakage of blood derived
toxic proteins into the brain [39]. These data suggest a
potential model of AD pathogenesis in which the
female sex and APOE ε4 allele contribute to
neuroinflammatory damage to the brain and brain
microvasculature, leading to increased tau and brain
atrophy in FACs.
Strikingly, although FACs had greater tau
deposition, we observed no differences in MMSE
score, global CDR and CDR-SOB between FACs and
NFACs. The implication that FACs exhibit increased
tau deposition without commensurate cognitive
decline warrants further investigation. This may
suggest that FACs experience greater cognitive
resilience to the effects of tauopathy compared to
males [24]. This is supported by a 18F-FDG PET study
in which cognitively normal female adults had a
younger metabolic brain age compared with males
[40].
We also evaluated sex by APOE ε4 interaction
effects on brain region-specific atrophy. FACs had a
significant lower gray matter volume in the cingulate,
medial temporal, inferior temporal and amygdala
cortex than the NFACs with AD after adjusting for
age and years of education. Previous studies have
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demonstrated that APOE ε4 allele is associated with
significantly lower hippocampal gray matter volume
in females with MCI and AD, but not in males [9, 25].
Consistent with past findings, our ROI-based and
voxelwise analysis showed that FACs had reduced
gray matter volume in several cortical regions
compared with the NFACs. Moreover, we also found
negative correlations between brain regional tau PET
uptake and grey matter volume, which is consistent
with existing studies [41, 42]. This suggests that tau
pathology is a major driver of local and distant
cortical atrophy [20, 43].
Table 2. Clusters with increased tau deposition among FACs with
AD
Clusters
Middle temporal/
L
Middle temporal pole/
Parahippocampal/
Entorhinal cortex/
Amygdala/
Inferior parietal/
Superior parietal/
Superior temporal/
Middle occipital/
Precentral.
Parahippocampal/
R
Middle temporal pole/
Inferior temporal/
Middle temporal/
Entorhinal cortex/
Amygdala.
Middle frontal/
L
Superior frontal/
Middle orbitofrontal.

Cluster size Atlas Coordinates
X
Y
Z
9892
-42
-54
60

Z score P value
6.27

< 0.001

1020

16.5

-4.5

-21

5.87

< 0.001

1416

-43

46

21

5.00

< 0.001

Notes: The data were extracted from voxels associated with maximally significant
18F-AV451 PET SUVR increases in FACs compared with the NFACs with AD, after
controlling for age and years of education. Cluster locations correspond to the brain
maps shown in Figure 3 and correspond to P < 0.001. Atlas coordinates were
obtained from the AAL atlas. The X, Y and Z coordinates are shown in the MNI
space. FACs: female APOE ε4 carriers.

Figure 4. The FACs had lower ROI gray matter volume relative to NFACs with AD. Mean (± standard deviation) of ROI gray matter volume for FACs (red) and
NFACs (blue) with AD are depicted. P values were determined by a generalized linear model with age, years of education were included as covariates. For consistency, the
regions displayed are those in which FACs have significantly higher ROI 18F-AV-1451 PET SUVRs from Figure 2. FACs: female APOE ε4 carriers, NFACs: non-FACs, SUVR:
standardized uptake value ratio.

http://www.thno.org
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Figure 5. Voxelwise difference of gray matter density between FACs and
NFACs with AD. T values are expressed along the blue-red scale from -5 to 0 (P <
0.001, adjusted for age and years of education). FACs: female APOE ε4 carriers,
NFACs: non-FACs.

Table 3. Clusters with decreased gray matter volume among
FACs with AD
Clusters

Inferior temporal/
Occipital.
Superior temporal pole
Superior temporal
Middle temporal
Amygdala
Middle occipital
Superior occipital/
Precuneus.
Posterior cingulate
Superior-medial
frontal/Supplementary
motor area/
Superior frontal.

Cluster
size

Z score P value

-4.04

< 0.001

L

653

Atlas coordinates
(peak)
X
Y
Z
-54
-52.5 -22.5

R
L
L
L
L
R

135
204
446
104
137
762

58.5
-63
-69
-17.5
-45
27

15
-3
-30
-4.5
-82.5
-84

-13.5
-9
1.5
-16.5
10.5
39

-3.78
-3.94
-4.10
-4.35
-4.16
-4.73

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

L
L/R

471
3003

-3
1.5

-46.5
54

19
42

-5.71
-5.41

< 0.001
< 0.001

Notes: The data were extracted from voxels associated with maximally significant
gray matter volume decreases in FACs compared to the NFACs with AD, after
controlling for age and years of education. Listed locations correspond to the brain
maps shown in Figure 5 and correspond to P < 0.001. Atlas coordinates were
obtained from the AAL atlas. The X, Y and Z coordinates are shown in the MNI
space. FACs: female APOE ε4 carriers, NFACs: non-FACs.

In the current study, we pooled data from female
APOE ε4 non-carriers, male APOE ε4 carriers and
male APOE ε4 non-carriers into a group labeled
NFACs. To evaluate whether similar results persist
when using not pooled data, we also analyzed group
comparisons for 18F-AV-1451 SUVRs between FACs
and female APOE ε4 non-carriers, male APOE ε4
carriers, male APOE ε4 non-carriers respectively. The
results from both “not pooled” and “pooled” data
were highly consistent across 6 out of the 8 originally
significant ROIs including the lateral temporal,
medial temporal, inferior temporal, entorhinal cortex,
amygdala and parahippocampal gyrus. In the “nonpooled” data, the SUVRs of posterior cingulate and

parietal showed a marginal P value between FACs
and female APOE ε4 non-carriers, male APOE ε4
carriers, male APOE ε4 non-carriers (posterior
cingulate: P = 0.07, 0.10, 0.08 and parietal: P = 0.12,
0.13, 0.09, respectively), but significant group
differences were observed after “pooling” the data (P
= 0.025 and 0.043). The findings suggest that the
increased sample size from pooling data enhanced the
study’s statistical power to discover FAC-associated
effects.
Limitations of this study must be considered
when interpreting the results. First, our analysis was
an observation study within the multicenter ADNI
cohort. The high biological and physiological
heterogeneity in AD related to age, sex and disease
stage, and the relatively small number of AD subjects
(15 FACs and 42 NFACs, all of whom received
18F-AV-1451 tau PET scans and APOE ε4 genotyping)
may limit the generalizability of results from the
study. For example, in our cohort the age range was
55-93 (78.98 ± 9.22 years) and CDR range was 0.5-2.0.
Given that the effects of sex and APOE ε4 are known
to vary significantly across disease stage and age
groups [44, 45], our results should be interpreted
within the age range in this cohort. It should be noted,
however, that the frequency of FACs was 26.3%,
which is comparable to an existing study [46]. Further,
due to its robustness within smaller sample sizes, a
GLM was used to assess group differences in tau
deposition and brain atrophy at both ROI and
voxelwise levels. We also evaluated the probability
that the current results are affected by sample size by
calculating the statistical power for tau SUVR to
distinguish FACs and NFACs. The statistical power
ranged from 0.725 to 0.999 with power > 0.8 in 10 out
of the 12 study ROIs. The statistical power for gray
matter volume to distinguish between the two groups
ranged from 0.220 to 0.999, with power > 0.8 in 5 out
of the 12 study ROIs. This suggests that tau-PET may
be more sensitive than spatial MRI to elucidate APOE
ε4 and sex effects in AD.
Considering the exploratory nature of our study,
our sample size and the correlated nature of the tau
positive study ROIs [47, 48], we choose to minimize
the probability of false negatives and include results
without multiple comparisons correction in the main
results. We recognize that this will increase our false
positive rate and have evaluated robustness to false
positives by applying the Benjamini-Hochberg
method for ROI based analyses and family wise error
(FWE) correction for voxelwise analyses. For the
ROI-based 18F-AV-1451 analysis, all regions remained
significant at false discovery rates (FDR) < 0.1 [24]. For
the ROI-based gray matter analysis, three regions i.e.
the amygdala, inferior temporal and posterior
http://www.thno.org
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Figure 6. Correlation between regional 18F-AV-1451 SUVR and gray matter volume in AD participants. Line graphs showing correlation between regional gray matter
volume (cm3) and 18F-AV-1451 SUVR. Fitted lines, P-values, and 95% confidence intervals are displayed from partial correlation analysis. SUVR: standardized uptake value ratio.

cingulate remained significant at FDR < 0.1. All
regions remained significant at FDR < 0.2. For the
voxelwise 18F-AV-1451 analysis, clusters in the right
inferior temporal, left amygdala, inferior parietal,
superior parietal, bilateral entorhinal cortex and
parahippocampal gyrus regions remained significant
after FWE correction. For the voxelwise gray matter
analyses, no clusters survived FWE correction.
Further, we acknowledge that the current work
is based on the ADNI cohort and may not generalize
to other AD patient populations. Future analyses
should be conducted in multi institutional cohorts
beyond ADNI with larger sample sizes to validate this
preliminary work.

Conclusion
In summary, sex modifies the effects of the
APOE ε4 allele on brain region-specific tau deposition
and gray matter volume in older adults with AD.

Specifically, FACs exhibited elevated brain
region-specific tau PET SUVR and deceased gray
matter volume. Results from this study advance our
understanding of the effect of sex and APOE ε4 in
promoting tau pathology in AD. Importantly, this
work highlights the importance of considering sex
and APOE ε4 in biomarker development, clinical trial
endpoint evaluation, and mechanistic studies in AD
using quantitative 18F-AV-1451 PET.
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